J. Goldman & Co’s Novavax NVAX Stock Holding History

J. Goldman & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,137	Closed	-$727K	–	453
2022 Q2	$727K	Buy	+14,137	New	+$732K	0.04%	265

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

J. Goldman & Co's NVAX Position: Q3 2022 in Review

J. Goldman & Co sold out of Novavax (NVAX) in Q3 2022, closing a stake of 14,137 shares — an estimated $727K sold.

J. Goldman & Co first reported a position in NVAX in Q2 2022 and held it in 1 quarter. The position peaked at $727K in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

J. Goldman & Co reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
J. Goldman & Co sold 14,137 Novavax shares in Q3 2022, an estimated $727K.
J. Goldman & Co first reported a position in Novavax in Q2 2022 and held it in 1 quarter.
J. Goldman & Co's Novavax position peaked at $727K in Q2 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.